Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases

Zhang, Kaiji; Lian, Ying; Guan, Xiaohong; Hu, Qian; Lei, Lihua; Li, Tao; He, Dong; Lin, Juan; Hou, Zheng; Ren, Liwei; Liu, Huan; Ren, Qian; Lin, Pang; Fei, Xiaoli; Mei, Xiong; Wen, Shunzhu; Cao, Jinzhu

doi:10.1007/s00277-020-04268-z

Cited by 2 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A subsequent phase 3b trial in 135 Chinese patients with de novo or secondary MDS showed 29.4% overall response rate (ORR) for 3‐h infusion at 15 mg/m 2 every 8 h for 3 consecutive days/cycle/6 weeks and 25.5% ORR for 1‐h infusion at 20 mg/m 2 once daily on days 1–5/cycle/4 weeks 10 . A recent retrospective study of 13 Chinese patients with de novo MDS showed 69.2% ORR with intravenous decitabine at 6 mg/m 2 per day for 7 days, repeated every 4 weeks 14 . Up to date, there has been no clinical trials of decitabine in Chinese patients with intermediate‐ or high‐risk de novo MDS.…”

Section: Introductionmentioning

confidence: 99%

“… 10 A recent retrospective study of 13 Chinese patients with de novo MDS showed 69.2% ORR with intravenous decitabine at 6 mg/m 2 per day for 7 days, repeated every 4 weeks. 14 Up to date, there has been no clinical trials of decitabine in Chinese patients with intermediate‐ or high‐risk de novo MDS. We conducted a multicenter, open‐label, dose comparison trial to compare the efficacy and safety of two decitabine dosing regimens (20 mg/m 2 /day for 5 consecutive days vs. 12 mg/m 2 /day for 8 consecutive days, every 4 weeks) in Chinese patients with intermediate‐ or high‐risk de novo MDS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

et al. 2023

View full text Add to dashboard Cite

show abstract

Immune thrombocytopenia in a patient with COVID-19

et al. 2020

View full text Add to dashboard Cite

This case report describes immune thrombocytopenic purpura in a 41-year-old man hospitalized in the intensive-care unit for COVID-19, 13 days after the onset of COVID-19 symptoms with respiratory failure at admission. Acute respiratory distress syndrome was treated with, among other drugs, low-molecular-weight heparin. On day 8, his platelet count began descending rapidly. On day 10, heparin treatment was replaced by danaparoid sodium, but by day 13, the continued low platelet count made a diagnosis of heparin-induced thrombocytopenia unlikely. Normocytic nonregenerative anemia gradually developed. On day 13, a bone marrow aspiration showed numerous megakaryocytes and a few signs of hemophagocytosis. Corticosteroids were introduced on day 14, and platelets began rising after 3 days and then fell again on day 19. Intravenous immunoglobulin (IV Ig) was then administered. Two days later, the platelet count returned to normal. The immune cause was confirmed by ruling out the differential diagnoses and the excellent and rapid response to intravenous immunoglobulins. Finally, the patient's respiratory state improved. He was discharged to a respiratory rehabilitation unit on day 38. Our case suggests that an immunological cause should be considered in patients with thrombocytopenia during COVID-19.

show abstract

Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases

Cited by 2 publications

References 28 publications

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

Immune thrombocytopenia in a patient with COVID-19

Contact Info

Product

Resources

About